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Myeloid blood cell production from hematopoietic stem and progenitor cells (1,
2) is regulated by a network of interacting accessory cell populations (1). Accessory
cells release biomolecules or cytokines, which in turn can act either directly on he-
matopoietic stem and progenitor cells (3-6), or indirectly on other accessory cells
(5, 7-10). Cytokines implicated in the modulation of blood cell production include,
but are not limited to, the hematopoietic colony-stimulating factors: granulocyte/mac-
rophage CSF (GM-CSF),' M-CSF, G-CSF, multi-CSF (also termed IL-3) and
erythropoietin, as well as IL-1 through IL-6, cachectin/TNFa, lymphotoxin/
TNF0, IFN-a, -0, and -,y, transforming growth factor 0, prostaglandins El, and
E2, lactoferrin, acidic isoferritin, activin, and inhibin (1-10). These well-character-
ized mediators have been shown to act on more than one cell type and to exert more
than one effect (1-10). New cytokines that act to regulate myelopoiesis are being de-
scribed as well. Herein we report a new and unique myelopoietic enhancing activity
in vitro for the recently descibed heparin-binding macrophage inflammatory pro-
teins, MIP-1 and MIP-2 (11-15) on granulocyte/macrophage progenitor cells (CFU-
GM) from bone marrows of normal mice and humans.
Materials and Methods
Cells and Cell Separation Procedures
Femoral bone marrow cells were obtained from 4-6-wk-old (C57B1/6 x DBA/2)Fj (BDF,)
female mice purchased from Cumberland View Farms (Clinton, TN). Cells were used as
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isolated or following purification as described elsewhere with minor modification (16). In short,
purified CFU-GM were obtained as follows: mice were injected intraperitoneally with 200
mg/kg cyclophosphamide, marrow cells were removed 3 d later, and the low density cells
(<1.077 g/cm3) were retrieved after density cut separation on Ficoll-Hypaque (Pharmacia
Fine Chemicals, Piscataway, NJ). The low density cells were then purified further by cen-
trifugal elutriation in a Sanderson Chamber at 4°C rather than 1OsC. In the present studies,
the peak CFU-GM-containing fractions elutriated at a slower sedimentation rate (16-20
ml/min) than previously reported (24-28 ml/min), but the yields and purity of CFU-GM
were similar.
Human bone marrow cells were obtained by aspiration from the posterior iliac crest of
healthy volunteers who had given informed consent according to the guidelines established
by the Human Investigation Committee of the Indiana University School of Medicine. Low
density marrow cells were purified on Ficoll-Hypaque and cultured.
Biomolecules and Antibodies
Natural murine (mu) MIP 1 (comprised of a and ,Q peptides) and MIP 2 were isolated
from the supernatant fluidof LPS-stimulated RAW 264.7 cellsand purified as described pre-
viously (11-14). Recombinant preparations of mu and human (hu) GM-CSF and muIL-4
(sp act, -108 U/mg each) (5) and huIL-6 (sp act, 5 x 106 U/mg) were kind gifts from Dr.
David Urdal and Dr. Steven Gillis, Immunex Corp., Seattle, WA. Natural muCSF1 (sp act,
2.3 x 107 U/mg) (5) was a kind gift from Dr. Richard K. Shadduck, University of Pitts-
burgh School of Medicine, Pittsburgh, PA. Recombinant huG-CSF (95% pure, sp act,
>5 x 10' U/mg) (5) was a kind gift from Dr. Peter Ralph and Dr. Robert Drummond, Cetus
Corp., Emeryville, CA. Recombinant huIL-1-a (sp act, 109 U/mg using the D10 cell assay)
(6) was a kind gift from Dr. Peter T. Lomedico, Hoffman-LaRoche, Nutley, NJ. The purified
Ig fractions of anti-MIP-1 and anti-MIP-2 (17) were prepared from serum ofrabbits injected
respectively with purified preparations of MIP-1 and MIP-2. Escherichia coli LPS was pur-
chased from Sigma Chemical Co., St. Louis, MO.
Colony Assays
CFU-GM
￿
Unseparated mouse bone marrow cells (0.5, 0.75, and 1.0 x 105 cells/ml) and
low density human bone marrow cells (1.0 x 105 cells/ml) were plated in standard 35-mm
standard tissue culture dishes in 1 ml of 0.3% agar (Difco Laboratories, Inc., Detroit, MI)
culture medium containing McCoy's 5A medium supplemented with additional essential and
nonessential amino acids, glutamine, serine, asparagine, sodium pyruvate (Gibco Laborato-
ries, Grand Island, NY) and 10% inactivated (56°C for 0.5 h) FCS (HyClone Laboratories,
Logan, UT) with or without purified growth factors (5). Purified murine CFU-GM were
plated at 200 cells/ml in 0.4% agarose (16). Serum-free culture conditions were as described
elsewhere (18). Culture dishes were incubated at 37°C in a humidified atmosphere flushed
with 5% C02 at lowered (5%) 02 tension and scored after 7 d for colonies (>50 cells/ag-
gregate) and clusters (5-50 cells/aggregate) for human and mouse cells, and also after 14 d
for human cells. Day 7 and day 14 colonies appear to derive from different human CFU-GM
progenitors (19, 20) and colonies plus clusters provide a more accurate estimate of the actual
number ofprogenitorcellsstimulated than sampling ofcolonies only (19). Colony and cluster
morphology were assessed in whole plates stained with a-naphthylacetate esterase and luxol
fast blue and counter-stained with hematoxylin (21). CFU-GM in DNA synthesis (S-phase)
were killed by pulse exposure to 50 uCi/ml high specific activity [3H]TdR (sp act, 20 Ci/
mmol; New England Nuclear, Boston, MA) as described (22, 23).
BFU-E.
￿
Mouse bone marrow cells (2 x 105 cells/ml) were plated in standard 35-mm
tissue culture dishes containing a 1-ml mixture of Iscove's modified Dulbeccds medium, 1.3
methylcellulose, 30% FCS, 5 x 10-5 M 2-ME, 0.1 mM hemin (Eastman Kodak Co., Roch-
ester, NY), and 2 U (r)erythropoietin (Amgen Corp., Thousand Oaks, CA) (22). Cultures
were incubated as above for CFU-GM and scored after 7 d of incubation.
Statistics
The results are expressed as the mean t 1 SEM ofthree plates per point for the CFU-GM
assay and four plates per point for the BFU-E assay. Levels of significance for comparisions
between samples were determined using student's t distribution.Results
Myelopoietic Enhancing Activities In Vitro ofMIP-1 and MIP-2.
￿
MIP-1 and MIP-2
were assessedalone and in combination, atvarious concentrations, for theirinfluence
on colony and cluster formation by mouse bone marrow CFU-GM stimulated with
suboptimal concentrations ofnmuCSF1 orrmuGM-CSR Representative resultsof
one of two identical sets of experiments are shown in Table I. MIP-1 and MIP-2
each significantly enhanced colony, and colony plus cluster, formation stimulated
by 10 U/ml of either nmuCSFl or rmuGM-CSR Maximal levels ofenhancement
were noted at 100-200 ng/ml MIP-1 or MIP-2 (Table I) and concentrations of up
to 1,000 ng/ml ofMIP-1 or MIP-2 did not furtherenhance colony or clusterforma-
tion (data not shown). No synergy was observed when MIP-1 and MIP-2 were as-
sayedin combination(Table I). Neither MIP-1 norMIP-2, atconcentrations ranging
from 100 to 300 ng/ml, stimulated colony or cluster formation of mouse marrow
CFU-GM in the absence ofan added source ofCSF (Table II). Both MIP-1 and
MIP-2 enhanced colony and cluster formation of mouse marrow CFU-GM max-
imally stimulated by nmuCSF1 or rmuCSF1 (100 U/ml oreither), but the percent
enhancement noted was not as much as that seen when colonies and clusters were
stimulated with suboptimal concentrations of either CSF (10 U/ml of each) (Table
II). The enhancing effects ofMIP-1 orMIP-2 were similarwhether coloniesorcolo-
nies plus clusters were evaluated except when 10 U/ml of nmuCSFl was used to
TABLE I
Influence of Various Concentrations of MIP-1 andMIP-2, Alone and
In Combination, on Colony and Cluster Formation by Mouse Bone
Marrow CFU-GM Stimulated In Vitro with CSF-1 or GM-CSF
BROXMEYER ET AL.
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CFU-GM per 7.5 x 104 BDFI cells stimulated with:
' p < 0.05 compared with control medium.
Additions
to culture Amount
nmuCSF-1
Colonies
(10 U)
Colonies
and clusters
rmuGM-CSF (10 U)
Colonies
Colonies and clusters
n8
Control medium 17 ± 2 64 ± 6 49 ± 2 61 t 3
MIP-1 200 40 t 4" 104 t 7' 79 t 5' 101 t 6'
MIP-1 100 35 t 2' 100 t 2' 79 t 1' 102 t 4'
MIP-1 50 22 t 2 57 t 6 64 t 3' 84 t 1'
MIP-1 25 16 t 1 51 t 1 59 t 2' 76 1 2'
MIP-1 12.5 17 1 1 64 1 6 47 f 3 61 t 3
MIP-1 6.25 17t 1 61 t4 48t2 6013
MIP-2 200 30 t 2' 109 t 6' 72 t 2' 89 f 2.
MIP-2 100 30 t 5" 103 t 5' 75 t 6' 97 t 3'
MIP-2 50 18 1 2 68 1 7 57 1 6' 71 1 6
MIP-2 25 16 t 1 59 1 3 47 1 2 60 1 3
MIP-2 12.5 18 1 3 60 1 2 45 1 3 57 1 4
MIP-2 6.25 16 1 2 61 t 1 46 1 3 59 1 4
MIP-1 + 6.25
MIP-2 6.25 15 t 1 58 ± 1 47 ± 2 61 t 3
MIP-1 + 100
MIP-2 100 32 t 2. 92 t 9' 81 t 5' 94 t 6'1586 MACROPHAGE INFLAMMATORY PROTEINS 1 AND 2 IN MYELOPOIESIS
stimulate the cells; in this case enhancement ofcolonies by MIP-1 or MIP-2 was
greater than the enhancement for colonies plus clusters (Table II). The enhancing
effects ofMIP-1 and MIP-2 were noted whether the cellswere plated in the absence
or presence of 10-6 M indomethacin (Table II, legend). The enhancing activity of
MIP-1 or MIP-2 was also apparent in the absence ofserum in the culture system,
with 200 ng ofeach significantly enhancing colony and colony plus cluster form-
ationby67-89% inthe presenceof100UnmCSF1 andby 77-122% in the presence
of 100 UrmuGM-CSF When the types ofcolonies and clusters enhanced byMIP-1
and MIP-2 were evaluated, it was evident that both those containing only macro-
phages, or containing both macrophages and neutrophils, were significantly (p <
0.001) enhanced byMIP-1 and MIP-2 (datafor five separate experiments notshown).
SpecificityofMIP-1 andMIP-2Myelopoietic EnhancingActivities.
￿
To substantiate that
the enhancingeffects notedwere due to MIP-1 and MIP-2 themselves, the prepara-
tions ofMIP-1 andMIP-2 were each preincubated withpurifiedIgfractions ofrabbit
anti-murine MIP-1 or rabbit anti-murine MIP-2 before their addition to cultures
containing 10U/mlofeither nmuCSFl orrmuGM-CSR The representativeresults
ofone or two similarexperiments are shownin Fig. 1. The antibodies by themselves
had no effect on CSFstimulated colony or clusterformation (p> 0.05). Anti-MIP-1
neutralized the myelopoietic enhancing activity of MIP-1, but not ofMIP-2, and
anti-MIP-2 neutralized the myelopoietic enhancing activity of MIP-2, but not of
MIP-1, suggesting thattheenhancingeffectsofMIP-1 and MIP-2were independent
and not due to contaminating molecules.
TABLE II
Influence of MIP-1 and MIP-2 on Colony and Cluster Formation by Mouse Bone Marrow
CFU-GM Co-stimulated In Vitro with CSF-1, GM-CSF, or G-CSF
Percent increase with MIP on numbers of CFU-GM
stimulated with CSF'
Results are expressed as the mean t 1 SEM, with numbers of experiments done shown
in parentheses, for BDFj mouse bone marrow cells plated at 5.0 x 104, 7.5 x 104, or 1 .0 x
10 cells/ml in the absence and presence of added CSF and in the absence or presence of
100-300 ng MIP-1 or MIP-2. Results were similar regardless ofthe cell concentration plated
or if cells were plated in the absence or presence of 10-6 M indomethacin and were there-
fore pooled. The percent increases are based on control CFU-GM numbers of. 0 colonies
and 0 to 8 t 1 colonies and clusters without CSF, 7 t 1 to 39 t 1 colonies and 30 t
1 to 120 t 10 colonies plus clusters with 10 U CSFA, 62 t 1 to 151 * 5 colonies and
109 t 6 to 313 t 13 colonies plus clusters with 100 U CSF-1, 19 t 1 to 49 t 2 colonies
and 28 t 1 to 103 t 5 colonies plus clusters with 10 U GM-CSF, 31 t 1 to 67 t 2 colonies
and 45 t 3 to 137 t 4 colonies plus clusters with 100 units GM-CSF, 8 t 1 to 15 t 3
colonies and 19 t 2 to 38 t 5 colonies plus clusters with 100 U G-CSF.
2 Increases for each experiment within these groups were statistically significant to ¢ < 0.01.
5 Increases for each experiment within these groups were statistically significant to P < 0.05 .
CSF Amount
Colonies
MIP-1 MIP-2
Colonies and clusters
MIP-1 MIP-2
None
nmuCSF-1
U
10 108
0(4)
t 20 (14)t
0(4)
146 t 46 (9)I
3
59
t
t
4(4)
9 (14)$
6
63
t 6(4)
t 7 (9)1
nmuCSF-1 100 33 t 5 (10)5 44 t 7 (5)5 39 t 3 (10)5 43 t 13 (5)5
rmuGM-CSF 10 55 t 7 (12)t 68 t 8 (8)2 57 t 6 (12)I 58 t 4(8)1
rmuGM-CSF 100 36 t 6 (7)5 40 t 4 (5)5 46 t 8 (7)5 41 t 7 (5)5
rhuG-CSF 100 7 1 7 (3) 4 1 4(3) 11 t 6 (3) 9 ± 4(3)Control Medium
Anti A813 1 (50 u919)
Anti MIP 2 (50 ugiq)
MIP 1 (100nq)
MIP 2 (t00nq)
Anti MIP 1 + MIP 1
Anti MIP 1 + MIP 2
Anti MIP 2 + MIP 1
Anti MIP 2 + UP 2
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￿
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FIGURE 1.
￿
Influence of anti-MIP-1 and anti-MIP-2 antibodies on the myeloid enhancing ac-
tivity of MIP-1 and MIP-2. Preparations of MIP were preincubated with control medium or
anti MIP for 1.5 h at room temperature before addition to culture dishes with 5 x 10'I BDFI
bone marrow cells/milliliter in thepresence ofnmuCSFl or rmuGM-CSF. Significant increases
in colony and colony plus duster formation (p < 0.001) were noted with MIP-1, MIP-2, anti-
MIP-1 plus MIP-2, andanti-MIP-2 plus MIP-1. Theothervalues were not significantly different
from control (p > 0.05).
While MIP-1 and MIP-2 enhanced CFU-GMcolony andclusterformationstimu-
lated by nmuCSF1 and rmuGM-CSF as noted above (TablesI and II), both MIP-1
and MIP-2were without effect on coloniesorclusters stimulated byrhuG-CSF (Table
11). Colonies and clusters stimulated by rhuG-CSF were >9517o composed ofonly
neutrophilic granulocytes. We also tested MIP-1 and MIP-2 for enhancement of
erythroidprogenitor cellproliferationbymousebone marrow erythroidburst-forming
units (BFU-E). In the absence of Epo, no BFU-E colonies formed in the absence
orpresence ofMIP-1 orMIP-2. NeitherMIP-1 nor MIP-2, atconcentrations ranging
from 1 to 1,000 ng/ml, enhanced BFU-E colony numbers or size in the presence
of0.25-2.0 Uof Epo (p > 0.05). Control BFU-E numbers formed in the absence
ofMIP-1 and MIP-2 but in the presence of2.0 U of Epo were, respectively, 25 t
1 and 25 t 2 per 2 x 105 BDFI mouse bone marrow cells plated in two separate
experiments.
The myelopoietic enhancingeffects ofMIP-1 and MIP-2 on mouse bonemarrow
cells were not mimicked by rhuIL-la, rmuIL-4, rhuIL-6, or E. coli LPS (data not
shown). rhuIL-laand rhuIL-6, both ofwhicharetitered foractivity on mousecells,
were each tested at 1, 5, and 10 ng/ml and were not found to significantly influence
colony orclusterformation stimulated with 10 U/ml ofnmuCSFl or rmuGM-CSF,
or 100 U/ml rhuG-CSF Moreover, neither 10 ng/ml of rhuIL-1a nor of rhuIL-6
significantly influenced colonies or clusters formed in thepresence of100ng/ml MIP-1
or MIP-2 with 10 U/ml ofnmuCSFl or rmuGM-CSE We have previously shown
that rmuIL-4only enhances mouse bone marrow neutrophil colony and clusterfor-1588 MACROPHAGE INFLAMMATORY PROTEINS 1 AND 2 IN MYELOPOIESIS
mation in the presence of rhuG-CSF; it does not enhance neutrophil, neutrophil-
macrophage, or macrophage colony orcluster formation stimulated withnmuCSF1
or rmuGM-CSF (5). E. coli LPS tested at 0.01-100,ug/ml (in 10-fold increments)
in the absence or presence of 10-6 M indomethacin did not enhance colony or
clusterformation stimulated by 10 U/ml nmuCSFl or rmuGM-CSF. LPS did sup-
press CSFstimulated colonies and clusters in a dose-dependent fashion with up to
93% inhibition apparent with 100 t~g LPS/ml. The LPS-induced suppression was
still apparent and only minimally counteracted when cells were plated with 10-6 M
indomethacin.
Influence ofMIP-1 andMIP-2on PurifiedPbpulations ofMouseMarrow CFU-GM.
￿
Since
CFU-GM makeup <0.5% ofthepopulation ofunseparated marrow cells (as is ap-
parent from the <0.5% colony and cluster cloning efficiency ofcells plated in the
presence of 100 Units/ml nmCSF1 or rmGM-CSF in Table II) it was not possible
to determine fromtheabove studieswhetherMIP-1 and MIP-2 were acting directly
on the CFU-GM, or indirectly through an action on accessory cells. To determine
whetherMIN and MIP-2 had direct acting effects on CFU-GM, mouse bone marrow
cells were purified (16) and the preparations ofthese two mediators were evaluated
fortheirinfluence oncolony and cluster formationby 200 purifiedcells plated/milliliter
and stimulated with 50 U/ml of either nmuCSFl or rmuGM-CSF. The results of
one representative oftwo similarexperiments are shown in Fig. 2. The colony plus
clustercloning efficiencies ofthevariousfractionsranged from 15 to44% when cells
were stimulated with nmuCSF1 and from 17 to 39% when cells were stimulated
with rmuGM-CSF These concentrations ofCSF (50 U/ml) result in maximal or
near maximal stimulation of colony and cluster formation by purified CFU-GM
when only one type ofCSF is used, although combinations ofCSFs can result in
higher cloning efficiencies (3). MIP-1 and MIP-2 (100 ng/ml) each significantly en-
hanced (p at least <0.01 when compared with cells in that particular fraction cul-
turedwith control medium)CSFstimulated colony andcluster formation bypurified
CFU-GM in thevarious fractions(Fig. 2). Cloningefficiencies ofup to 82 and 65%
were respectively noted forcells plated inthe presence ofMIPplus either nmuCSFl
or rmuGM-CSF Theseresults suggestthat MIP-1 and MIP-2 probably exert direct
acting effects on mouse marrow CFU-GM in vitro.
Cell Cycle-relatedMyelopoietic EnhancingActivities ofMIRI andMIP-2.
￿
To evaluate
whetherMIP-1 and MIP-2had preferential effects on CFU-GM in S-phase orduring
non-S-phase portions ofthe cell cycle, mousebonemarrow cells were pulse treated
with nonradioactive (cold) thymidine (shown to have no effect on subsequent colony
orclusterformation by thecells [22, 23]) orhigh specific activitytritiatedthymidine
before washingandplatinginthepresence of10or 100U/mlofnmuCSF1 orrmuGM-
CSF and in the absence or presence of 100 ng/ml MIP-1 or MIP-2. Table III shows
the data from one oftwo experiments with similar results. Both MIP-1 and MIP-2
significantly enhanced colony and cluster formation by cells first pulsed with cold
thymidine. In contrast, CFU-GM in DNA synthesis (S-phase) at the time ofpulse
exposure with high specific activity [3H]TdR are reproductively killed and only
CFU-GM not in S-phase ofthe cellcycleat that time go onto proliferate in response
to CSF toformacolony orcluster. MIP-1 and MIP-2 hadno myelopoietic enhancing
activity on cells that were first pulse treated with high specific activity [3H]TdR toBROXMEYER ET AL .
FIGURE 2 .
￿
Influence of MIP-1 and MIP-2 on colony and cluster formation of purified mouse
CFU-GM stimulated bynmuCSRl orrmuGM-CSF. MouseCFU-GM werepurified as described
elsewhere (16) .
TABLE III
Influence of MIP-1 and MIP-2 on Untreated Mouse Bone Marrow CFU-GM
versus Bone Marrow Depleted of CFU-GM in S-Phase
Cells were pulse treated with cold thymidine or high specific activity [ 3H]TdR as described
in Materials and Methods, washed, and plated at 5 x 104 cells/ml in the presence ofCSF and
in the absence and presence of MIP-1 or MIP-2 .
Significant increase from control medium,p< 0.01 ; other numbers are not significant, p> 0.05 .
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Cells plated with
Colonies
Cold TdR [3H]TdR
Colonies
Cold TdR
& clusters
[3H]TdR
A) nmuCSF-1 (10 U)
Control medium 18 1 2 7 t 1 60 ± 2 36 ± 3
MIP-1 (200 U) 32 1 2' 6 t 1 105 ± 5' 32 ± 2
MIP-2 (200 U) 30 f 2' 8 t 1 100 ± 4" 32 ± 3
B) nmuCSF-1 (100 U)
Control medium 125 t 4 49 f 3 313 t 13 180 t 17
MIP-1 (200 U) 167 t 9" 45 t 2 414 t 7' 153 t 10
MIP-2 (200 U) 181 t 12' 52 t 2 410 t 15' 196 t 9
C) rmuGM-CSF (10 U)
Control medium 41 t 1 14 t 2 69 1 3 30 f 3
MIP-1 (200 U) 66 t 3' 13 t 2 107 t 7' 30 t 4
MIP-2 (200 U) 72 t 4' 13 t 1 104 t 3' 32 t 2
D) rmuGM-CSF (100 U)
Control medium 58 ± 4 26 1 2 70 1 2 39 1 3
MIP-1 (200 U) 89 t 3' 25 t 2 106 t 3' 40 t 4
MIP-2 (200 U) 84 f 3' 24 t 1 99 t 1` 35 t 11590 MACROPHAGE INFLAMMATORY PROTEINS I AND 2 IN MYELOPOIESIS
TABLE IV
Influence ofMIP-1 and MIP-2 on Colony and Cluster Formation
by Normal Human Bone Marrow Cells
Day 7 CFU-GM
105 Low density cells/ml were plated in the absence and presence of 100 U CSF and 200 ng MIP and
scored for colonies and colonies plus clusters after 7 d ofincubation and for colonies after 14 d ofincubation.
Significant increase compared with control medium, p < 0.01 ; other values are not significantly different
from control, p > 0.05 .
remove S-phase CFU-GM. These results suggest that the myelopoietic enhancing
activities of MIP-1 and MIP-2 are initiated mainly or entirely during the DNA syn-
thetic phase of the CFU-GM cell cycle.
Influence ofMIP-1 and MIP-2 on Colony and Cluster Formation by Human Bone Marrow
CFU-GM. MIP-1 and MIP-2 (200 ng/ml) were evaluated for their effects on colony
and cluster formation by CFU-GM present in the low density fraction of normal
human bone marrow (Table IV). Cells were plated at 105 cells/ml in the absence
or presence of 100 U/ml rhuGM-CSF or rhuG-CSF and scored after 7 and 14 d
ofincubation. Low density human bone marrow cellscan form colonies and clusters
in the absence of an exogenously added source of CSF, but the numbers of colonies
and clusters formed are related to the number of cells plated and are a result of
the endogenous release ofCSFs from marrow accessory cells (24). In the two experi-
ments shown, MIP-1 and MIP-2 in the absence of added CSF significantly enhanced
colony formation when colonies formed in the absence of MIP, but not when colo-
nies did not form in the absence of MIP MIP-1 and MIP-2 each enhanced cluster
formation in the absence ofexogenously added CSF MIP-1 and MIP-2 significantly
enhanced colony and cluster formation by day 7 and day 14 CFU-GM stimulated
with rhuGM-CSF, but similar to the results noted for mouse colony and cluster for-
mation stimulated by G-CSF (Table II), neither MIP-1 nor MIP-2 enhanced colony
or cluster formation of human bone marrow cells stimulated with rhuG-CSF
Discussion
The heparin-binding proteins MIP-1 and MIP-2 have been shown to elicit a local-
ized inflammatory response when injected subcutaneously into footpads ofC3H/HeJ
Material added
to plate Colonies
Exp. 1
Colonies and
clusters Colonies
Exp. 2
Colonies and
clusters
Day 14 CFU-GM
Exp. 1 Exp. 2
Colonies Colonies
A. No CSF
Control medium 0 239 1 22 0 149 1 9 37 1 2 0
MIP-1 0 365 1 16' 0 223 1 13' 58 1 2' 0
MIP-2 0 355 1 8' 0 170 1 2' 54 1 6' 0
B. rhuGM-CSF
Control medium 50 1 3 304 1 9 16 1 2 162 1 5 68 1 3 24 ± 4
MIP-1 88 1 6' 409 1 11` 24 1 2' 179 t 9 125 t 5` 49 t 6'
MIP-2 80 t 7' 398 t 15' 25 t 3' 173 t 8 110 t 10' 45 t 3'
C. rhuG-CSF
Control medium 29 1 2 183 7 16 1 1 72 1 7 40 1 3 16 1 4
MIP-1 31 1 3 179 7 17 1 1 70 1 5 39 1 3 14 1 3
MIP-2 32 1 2 191 1 9 15 1 1 66 1 5 38 1 4 15 1 2BROXMEYER ET AL.
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mice(11, 13). MIP-1 actsasaprostaglandin-independent endogenous pyrogen when
administered tomice(15)and is capablein vitroofinducing chemokinesis ofhuman
neutrophils and oftriggeringadherent neutrophilsto releasehydrogen peroxide(11).
MIP-2 acts asa chemotactic agent for neutrophils and induces neutrophil degranu-
lation oflysozyme, but not of beta-glucuronidase (13).
The results presented here demonstrate a new and as yet unique role for MIP-1
andMIP-2at the level ofthe granulocyte/macrophage progenitor cell. WhileMIP-1
and MIP-2 had nohematopoieticCSFactivity when tested alone, theydidsignificantly
enhance colony and cluster formation by murine bone marrow CFU-GM co-
stimulated with nmuCSF1 and rmuGM-CSF and by human bone marrow CFU-
GM costimulated with rhuGM-CSF Studies using purified mouse marrow CFU-
GM suggested that the myelopoietic enhancing effects ofMIP-1 and MIP-2 were
due to a direct effect on the CFU-GM itself. The exact manner and mechanism
ofaction ofMIP-1 and MIP-2 on CFU-GM remains to be determined, but the ac-
tion appears to be mediated, or at least initiated, during S-phase ofthe cell cycle.
The fact that MIP-1 and MIP-2 can act directly on CFU-GM does not however
rule out the possibility that MIP-1 and MIP-2 might be able also to modulate my-
elopoiesis indirectly through an action on accessory cells.
A numberofmolecules withoutCSFactivity can modulate myelopoiesis inaposi-
tive fashion, but the type ofenhancing activity noted for MIP-1 and MIP-2 was
not duplicated in our hands by IL-la, IL-6, or bacterial LPS. We had previously
shown that IL-4 synergizes with G-CSF to enhance neutrophil colony formation
(5), but MIP-1 and MIP-2did not enhancethe activity ofrhuG-CSF against mouse
or human bone marrow cells, and IL-4does notenhance the activitiesofnmuCSF1
and rmuGM-CSF (5). IL-5 acts asaneosinophil-CSF (25; Lu, L., Z. H. Lin, R. N.
Shen, D. J. Warren, T Leemhuis, and H. E. Broxmeyer, manuscript in prepara-
tion) andMIP-1 and MIP-2didnot stimulate orenhance eosinophil colony orcluster
formation in our studies. IL-2 has not been shown to directly enhance CFU-GM
numbers(1). In thetype ofassay used in the present studies, cachectin/TNFa, lym-
photoxin/TNFfl, interferons, and acidic isoferritin suppress colony formation (1,
4). Activin enhances and inhibin suppresses BFU-E colony formation by an action
mediated through T lymphocytes and monocytes, but has no effect on CFU-GM
colony formation (10), and MIP-1 and MIP-2 had no demonstratable effect on
BFU-E colony formation. E-type prostaglandins 1 and 2 enhance Epo-dependent
BFU-E, but suppress CSFdependent CFU-GM colony formation(21). The reported
effectsoftransforming growth factor9 (26, 27) are alsonot consistent with the effects
noted herein for MIP-1 and MIP-2.
MIP-1 and MIP-2have predictedamino acid sequence homology with a number
ofothermolecules activatedin Tlymphocytes, includingLD78,JE, andTCA3 (12).
It will be of interest to see if these latter molecules have myelopoietic modulatory
activities also. To be determined, as well, is whether MIP-1 and MIP-2 can act in
vivo to enhance hematopoietic progenitor cell cycling and myelopoiesis.
Summary
Two recently identified and purified murine macrophage inflammatory proteins
MIP-1 andMIP-2 were tested in vitro both alone, and in combinationwith purified
recombinant (r) murine (mu) GM-CSF, natural (n)muCSF1, or rhuman (hu)G-1592 MACROPHAGE INFLAMMATORY PROTEINS 1 AND 2 IN MYELOPOIESIS
CSF, for effects on mouse marrow CFU-GM, in combination with erythropoietin
for effects on mousemarrow BFU-E, and in combination with rhuGM-CSF or rhuG-
CSF for effects on human marrow CFU-GM. MIP-1 and MIP-2 did not stimulate,
but did enhance by up to threefold, colony formation ofmouseCFU-GM co-stimulated
by rmuGM-CSF and nmuCSF1, but not by rhuG-CSF, in the absence or presence
of serum. MIP-1 and MIP-2 were maximally active at concentrations >100 ng/ml
and the actions appeared to be initiated during the DNA synthetic portion of
the cell cycle. Neither MIP-1 nor MIP-2 at up to 1 hg/ml had any effect on mouse
BFU-E, in the absence or presence of erythropoietin. Both MIP-1 and MIP-2 had
direct acting effects on purified mouseCFU-GM. The cloning efficiency of200 purified
cells plated with 50 U muCSF1 was 82% with and 43% without MIP; the cloning
efficiency with 50 U rmuGM-CSF was 65% with and 35% without MIP MIP effects
were not mimicked by bacterial LPS, rhuIL-ltx, rhuIL-6, or rmuIL-4, and were neu-
tralized by their respective specific antibodies. MIP-1 and MIP-2 also enhanced en-
dogenously stimulated and rhuGM-CSF, but not rhuG-CSF, stimulated colony
formation by human marrow CFU-GM. These results demonstrate a new role for
MIP-1 and MIP-2 in vitro as myelopoietic enhancing activities for CFU-GM.
We thank Kirk Manogue for helpful comments on the manuscript and Becki Robling for
typing the manuscript.
Receivedfor publication 6 June 1989.
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